PainChek Ltd. engages in the development and commercialization of mobile medical device applications. The company is headquartered in Sydney, New South Wales. The company went IPO on 2012-05-01. The firm's principal activities are development and commercialization of mobile medical device applications that provide pain assessment for individuals that are unable to communicate with their carers. The firm's PainChek Universal is a complete point-of-care solution that combines the existing PainChek Application with the numerical rating scale (NRS). PainChek Application uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalize pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the NRS, a standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.